MAP-4343
- Generic Name
- MAP-4343
MAP4343 Treatment for Alcohol Use Disorder
Phase 2
Withdrawn
- Conditions
- Alcohol Use Disorder
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- The Scripps Research Institute
- Registration Number
- NCT04157114
- Locations
- 🇺🇸
The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research, La Jolla, California, United States
RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Mapreg
- Target Recruit Count
- 110
- Registration Number
- NCT03870776
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷CHU Besançon, Besançon, France
🇫🇷CHD Vendée, La Roche-sur-Yon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath